icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
XUWG4u5jqg4Kcvse